MorphoSys AG - American Depositary Shares (NQ:MOR)

18.96 UNCHANGED

Last Price Updated: 4:00 PM EDT, Aug 2, 2024 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about MorphoSys AG - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >

Morpheus Launches $20 Million In Rewards For AI Compute Providers ↗

December 11, 2024

Morpheus, a decentralized platform for deploying AI-driven “Smart Agents,” has launched a $20 million reward program for compute providers.

Via Benzinga

Topics Artificial Intelligence

Merger Squeeze-Out of MorphoSys Minority Shareholders Approved at 2024 Annual General Meeting

August 27, 2024

Via ACCESSWIRE

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SILK, MOR, AFBI on Behalf of Shareholders

July 17, 2024

From Halper Sadeh LLC

Via GlobeNewswire

3 Global Stocks to Buy to Escape the Volatility on Wall Street ↗

July 16, 2024

Discover three top global stocks as a smart hedge against Wall Street volatility, offering diversification and resilience in uncertain times.

Via InvestorPlace

MorphoSys: Q4 Earnings Insights ↗

March 13, 2024

Via Benzinga

Earnings Outlook For MorphoSys ↗

March 12, 2024

Via Benzinga

Invitation to MorphoSys' Full Year Results 2023 Conference Call on March 14, 2024

March 07, 2024

Via ACCESSWIRE

MorphoSys Announces Voluntary Delisting from the Nasdaq Global Market

July 12, 2024

From MorphoSys AG

Via Business Wire

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates DM, SHCR, MOR, ALE on Behalf of Shareholders

July 08, 2024

From Halper Sadeh LLC

Via GlobeNewswire

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ALLG, MOR, BEST, MGOL on Behalf of Shareholders

June 29, 2024

From Halper Sadeh LLC

Via GlobeNewswire

MOR STOCK ALERT: Halper Sadeh LLC Is Investigating Whether the Sale of MorphoSys AG Is Fair to Shareholders

June 20, 2024

From Halper Sadeh LLC

Via Business Wire

MorphoSys and Novartis Sign Delisting Agreement and Intend to Implement a Merger Squeeze-out of MorphoSys’ Minority Shareholders

June 20, 2024

From MorphoSys AG

Via Business Wire

Ad hoc: Novartis BidCo Germany AG Intends to Implement a Merger Squeeze-out of MorphoSys AG’s Minority Shareholders

June 19, 2024

Via ACCESSWIRE

12 Health Care Stocks Moving In Monday's After-Market Session ↗

May 27, 2024

Via Benzinga

MOR Stock Earnings: MorphoSys Misses EPS, Misses Revenue for Q1 2024 ↗

April 30, 2024

MOR stock results show that MorphoSys missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.

Via InvestorPlace

MorphoSys AG Reports First Quarter 2024 Financial Results

April 29, 2024

From MorphoSys AG

Via Business Wire

MorphoSys Says Novartis Deal Progressing Steadily Despite Safety Concerns Over Bone Marrow Cancer Drug, Pelabresib ↗

April 29, 2024

MorphoSys faces safety concerns over pelabresib, a myelofibrosis treatment. Physicians report patients transitioning rapidly to acute myeloid leukemia. FDA alerted. Novartis acquisition proceeds...

Via Benzinga

MorphoSys To Present New Phase 3 MANIFEST-2 Data on Pelabresib in Myelofibrosis in Oral Presentation at 2024 ASCO Annual Meeting

April 24, 2024

Via ACCESSWIRE

Incyte Should Consider Significant Stock Buyback And Prioritize R&D, Analyst Recommends ↗

April 23, 2024

Incyte acquires Escient Pharmaceuticals for $750 million, bolstering its pipeline. Cantor Fitzgerald initiates coverage with a Neutral rating, citing undervaluation concerns despite strong cash flow.

Via Benzinga

MorphoSys’ Management Board and Supervisory Board Recommend Shareholders Accept Public Takeover Offer by Novartis

April 11, 2024

From MorphoSys AG

Via Business Wire

MorphoSys' Management Board and Supervisory Board Recommend Shareholders Accept Public Takeover Offer by Novartis

April 11, 2024

Via ACCESSWIRE

MorphoSys Announces U.S. Antitrust Clearance of Proposed Acquisition by Novartis Under HSR Act

March 21, 2024

Via ACCESSWIRE

MorphoSys AG Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

March 13, 2024

From MorphoSys AG

Via Business Wire

Earnings Scheduled For March 13, 2024 ↗

March 13, 2024

Companies Reporting Before The Bell • Sangamo Therapeutics (NASDAQ:SGMO) is likely to report quarterly loss at $0.26 per share on revenue of $8.10 million.

Via Benzinga

5 Biotechnology Stocks To Buy For A Stable Portfolio In 2024 ↗

March 09, 2024

Things have been looking better for the biotech industry in 2024 after a decent performance in 2023. Here is a look at some biotech stocks that may provide stability to one's portfolio throughout the...

Via Talk Markets

3 Cancer-Fighting Biotech Stocks Showing Clinical Trial Promise ↗

March 07, 2024

Discover the pivotal roles of cancer-fighting biotech stocks that are advancing cancer research and subsequently, their financial growth.

Via InvestorPlace

Exit Now! 3 Biotech Stocks to Sell in February 2024 ↗

February 21, 2024

These biotech stocks to sell represent incredibly risky bets, amidst the sector's volatility and looming economic unpredictability.

Via InvestorPlace

Novartis Agrees To Acquire German Blood Cancer-Drug Developer MorphoSys For €2.7B ↗

February 06, 2024

Novartis' €2.7 billion public takeover offer for MorphoSys, unlocking a promising oncology pipeline with pelabresib and tulmimetostat.

Via Benzinga

Biotech Stock MorphoSys Catapults 56% As Novartis Agrees To Buy It For $2.9 Billion ↗

February 05, 2024

Novartis will add to its cancer treatment pipeline with via the German biotech.

Via Investor's Business Daily

Why Is MorphoSys (MOR) Stock Up 50% Today? ↗

February 05, 2024

News of a potential takeout bid for any company usually leads to a big surge. That's what investors are seeing today with MOR stock.

Via InvestorPlace

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.